Jiangsu Nhwaluokang Pharmaceutical Research and Development

Jiangsu Nhwa Luokang Pharmaceutical Research and Development is the core innovative research arm of Jiangsu Nhwa Pharmaceutical, a prominent Chinese pharmaceutical company specializing in central nervous system (CNS) therapies. The company focuses on the discovery and clinical development of novel small molecule drugs targeting anesthesia, analgesia, and various psychiatric and neurological disorders. Based in Xuzhou, Jiangsu, the facility integrates medicinal chemistry, pharmacology, and early-stage clinical research to drive the parent company's transition toward an innovation-led portfolio. Notable achievements include the development and successful Chinese market entry of Oliceridine, a novel mu-opioid receptor agonist licensed from Trevena. The company maintains a robust pipeline of candidates in various stages of clinical trials, aiming to address significant unmet medical needs in the CNS space within the Chinese market.